Novel Precision-based Treatments For Biliary Tract Cancer
Funder
National Health and Medical Research Council
Funding Amount
$644,241.00
Summary
Advanced biliary tract cancer has a median life-expectancy of ~12 months. The relatively low incidence of the disease in Australia requires a collaborative team-based approach to drive progress. To achieve this, we have established a multidisciplinary research team based in Australia, Thailand and Japan. Here, we will now build on our exciting preliminary discoveries to test new patient-specific treatments, and develop methods to efficiently identify patients who may respond to immunotherapy.
Olanzapine For Young PEople With ANorexia Nervosa: An Open-label Feasibility Study To Test Recruitment, Treatment Acceptance, Adherence, Safety, Outcome Measures And Patients' Experience To Prepare For A Randomised Placebo-controlled Trial (OPEN)
Funder
National Health and Medical Research Council
Funding Amount
$190,799.00
Summary
Olanzapine seems to be a helpful and safe medication in anorexia nervosa (AN), but it is not approved for AN. We will perform a preliminary study with 70 patients with AN (15 in Australia and 50 in the UK, age: 12-24 years) who can safely take olanzapine and have not gained sufficient weight or experienced improvement in their AN symptoms under specialist care. We will the acceptability and feasibility of olanzapine in AN. Patients will be examined after 8 and 16 weeks, 6 months and 12 months.